Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Cooper

Showing results (71-80 of 399) with videos related to

Pageof 40
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|June 18, 2003
MK-767. Kyorin/Banyu/MerckAnna C Calkin, Merlin C Thomas, Mark E Cooper
Annals of the New York Academy of Sciences|July 23, 2005
Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?Melinda T Coughlan, Mark E Cooper, Josephine M Forbes
Current Diabetes Reports|November 13, 2004
Use of genetic mouse models in the study of diabetic nephropathyTerri J Allen, Mark E Cooper, Hui Y Lan
Cell Metabolism|February 8, 2023
The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetesMerlin C Thomas, Melinda T Coughlan, Mark E Cooper
Nature Reviews. Nephrology|July 20, 2021
Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney functionEoin Brennan, Phillip Kantharidis, Mark E Cooper, et al.
Hypertension (Dallas, Tex. : 1979)|January 14, 2004
Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptorsXiaoli Zhang, Markus Lassila, Mark E Cooper, et al.
American Journal of Therapeutics|November 11, 2005
Advanced glycation end products and diabetic nephropathyMerlin C Thomas, Josephine M Forbes, Mark E Cooper
Antioxidants & Redox Signaling|December 23, 2006
Renal microvascular injury in diabetes: RAGE and redox signalingMelinda T Coughlan, Mark E Cooper, Josephine M Forbes
Diabetes|May 31, 2008
Oxidative stress as a major culprit in kidney disease in diabetesJosephine M Forbes, Melinda T Coughlan, Mark E Cooper
International Journal of Molecular Sciences|February 26, 2025
High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?Ke Liu, Mark E Cooper, Zhonglin Chai, et al.
Pageof 40

Showing results (71-80 of 399) with videos related to

Sort By:
Pageof 40
Current Opinion in Investigational Drugs (London, England : 2000)|June 18, 2003
MK-767. Kyorin/Banyu/MerckAnna C Calkin, Merlin C Thomas, Mark E Cooper
Annals of the New York Academy of Sciences|July 23, 2005
Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?Melinda T Coughlan, Mark E Cooper, Josephine M Forbes
Current Diabetes Reports|November 13, 2004
Use of genetic mouse models in the study of diabetic nephropathyTerri J Allen, Mark E Cooper, Hui Y Lan
Cell Metabolism|February 8, 2023
The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetesMerlin C Thomas, Melinda T Coughlan, Mark E Cooper
Nature Reviews. Nephrology|July 20, 2021
Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney functionEoin Brennan, Phillip Kantharidis, Mark E Cooper, et al.
Hypertension (Dallas, Tex. : 1979)|January 14, 2004
Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptorsXiaoli Zhang, Markus Lassila, Mark E Cooper, et al.
American Journal of Therapeutics|November 11, 2005
Advanced glycation end products and diabetic nephropathyMerlin C Thomas, Josephine M Forbes, Mark E Cooper
Antioxidants & Redox Signaling|December 23, 2006
Renal microvascular injury in diabetes: RAGE and redox signalingMelinda T Coughlan, Mark E Cooper, Josephine M Forbes
Diabetes|May 31, 2008
Oxidative stress as a major culprit in kidney disease in diabetesJosephine M Forbes, Melinda T Coughlan, Mark E Cooper
International Journal of Molecular Sciences|February 26, 2025
High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?Ke Liu, Mark E Cooper, Zhonglin Chai, et al.
Pageof 40